This means that passive immunization with tau antibodies is actually a viable therapeutic target and which the CSF level of p-tau262/356 or with the microtubule binding area (MTBD) can serve as a useful biomarker of tau pathology to monitor tau therapeutics in clinical trials. Since the leading o